February 24, 2026/
Significant label update regarding mesalazine and idiopathic intracranial hypertension, a detailed local case report on warfarin-food interaction leading to ischemic stroke
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Significant label update regarding mesalazine and idiopathic intracranial hypertension, a detailed local case report on warfarin-food interaction leading to ischemic stroke
At its January 2026 meeting, PRAC adopted important new safety information concerning three distinct medicinal products: cefazolin (and cefazolin with lidocaine), erdatinib, and pegylated liposomal doxorubicin.
Based on the EMA Guideline on Good Pharmacovigilance Practices (GVP) Chapter P.III – Product- or Population-Specific Considerations III
